Tumor cells may inhibit ADCC mediated by anti‐CD38 monoclonal antibodies through the PD‐L1/PD‐1 pathway, and the subsequent upregulation of CD38 expression can inhibit CD8 T cells. Here, CD38 is linked to neoplasm.